Clinical

Dataset Information

0

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn’s Disease


ABSTRACT: A Phase 2b study to evaluate the efficacy and safety of brazikumab (MEDI2070) in participants with moderate to severe Crohn’s disease who have failed or are intolerant to anti-tumor necrosis factor-alpha (anti-TNFα) therapy.

DISEASE(S): Crohn's Disease,Crohn Disease

PROVIDER: 2200013 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-10-07 | GSE215067 | GEO
| 2134183 | ecrin-mdr-crc
2017-07-07 | E-GEOD-100833 | biostudies-arrayexpress
2010-07-23 | E-GEOD-17301 | biostudies-arrayexpress
2023-04-26 | E-MTAB-12788 | biostudies-arrayexpress
2018-05-22 | E-MTAB-5790 | biostudies-arrayexpress
2017-07-07 | GSE100833 | GEO
| 2154083 | ecrin-mdr-crc
2020-12-22 | E-MTAB-8901 | biostudies-arrayexpress
2021-04-07 | GSE148233 | GEO